Skip to Main Content

Author Details

Geert J L H van Leenders
Erasmus MC Cancer Institute, University Medical Center
1998
269
55
PMIDPaper TitleJournal TitlePublished Year
37877215Origin and outcome of metastatic tumours to the testes: a nationwide study.BJU Int2024
37558528Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools.Clin Genitourin Cancer2024
36226695Myoid gonadal stromal tumours are characterised by recurrent chromosome-level copy number gains: molecular assessment of a multi-institutional series.Histopathology2023
37760487Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic Review.Cancers (Basel)2023
37719014GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches.Front Oncol2023
37188780Pelvic lymph node dissection for cervical or bladder cancer: embedding residual fat tissue offers no added value.Virchows Arch2023
37453276Association of quantifiable prostate MRI parameters with any and large cribriform pattern in prostate cancer patients undergoing radical prostatectomy.Eur J Radiol2023
37117107Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review.Eur Urol2023
37312054The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.BMC Cancer2023
37140551Biopsy prostate cancer perineural invasion and tumour load are associated with positive posterolateral margins at radical prostatectomy: implications for planning of nerve-sparing surgery.Histopathology2023
37400554The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies.Sci Rep2023
37032279Urinary Incontinence and Sexual Function After the Introduction of NeuroSAFE in Radical Prostatectomy for Prostate Cancer.Eur Urol Focus2023
37195595Impact of comedonecrosis on prostate cancer outcome: a systematic review.Histopathology2023
36651339Long-term follow-up of contemporary drug-eluting stent implantation in diabetic patients: Subanalysis of a randomized controlled trial.Catheter Cardiovasc Interv2023
36874601Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.Eur Urol Open Sci2023
36645163Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria.Histopathology2023
36865297Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients.medRxiv2023
36631536The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates.Prostate Cancer Prostatic Dis2023
36939057Cribriform morphology is associated with higher risk of biochemical recurrence after radical prostatectomy in patients with Grade Group 5 prostate cancer.Histopathology2023
36382415Combined germline pathogenic variants in FLCN and TP53 are associated with early onset renal cell carcinoma and brain tumors.Mol Genet Genomic Med2023
34717190Improving the prediction of biochemical recurrence after radical prostatectomy with the addition of detailed pathology of the positive surgical margin and cribriform growth.Ann Diagn Pathol2022
35384019Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.Histopathology2022
35803346Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection.Urology2022
35800157Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.Oncoimmunology2022
35341658A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men.Eur Urol2022
35536200NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome.BJU Int2022
35421819Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands.Cancer Treat Res Commun2022
35654644Corrigendum to "Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study".Urol Oncol2022
36429059Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling.Cells2022
35900850Clinicopathologic Spectrum of Secondary Solid Tumors of the Prostate of Nonurothelial Origin: Multi-institutional Evaluation of 85 Cases.Am J Surg Pathol2022
36190529Percentage Gleason pattern 4 and PI-RADS score predict upgrading in biopsy Grade Group 2 prostate cancer patients without cribriform pattern.World J Urol2022
36083240Low-grade prostate cancer should still be labelled cancer.BJU Int2022
33811730Clinical outcomes after permanent polymer or polymer-free stent implantation in patients with diabetes mellitus: The ReCre8 diabetes substudy.Catheter Cardiovasc Interv2022
35157140Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.Virchows Arch2022
35032896Infantile fibrosarcoma with an EGFR kinase domain duplication: Underlining a close relationship with congenital mesoblastic nephroma and highlighting a similar morphological spectrum.Ann Diagn Pathol2022
35088185Differential Diagnosis and Molecular Stratification of Gastrointestinal Stromal Tumors on CT Images Using a Radiomics Approach.J Digit Imaging2022
34906411Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.Urol Oncol2022
34706119Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.Histopathology2022
34615720Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells.Clin Cancer Res2022
34374824Efficacy of coronary sinus Reducer in patients with refractory angina and diabetes mellitus.Heart Vessels2022
32815034Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome.Virchows Arch2021
33547623Acute recoordination rather than functional hemodynamic improvement determines reverse remodelling by cardiac resynchronisation therapy.Int J Cardiovasc Imaging2021
33909149PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.Virchows Arch2021
33789933GRPr Antagonist <sup>68</sup>Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients.J Nucl Med2021
33780691Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts.Ann Diagn Pathol2021
34891161Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA-minus RNA sequencing data.Gigascience2021
34977692Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy.Eur Urol Open Sci2021
34715822Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.BMC Cancer2021
347946543-Year Clinical Outcomes After Implantation of Permanent-Polymer Versus Polymer-Free Stent: ReCre8 Landmark Analysis.JACC Cardiovasc Interv2021
34157072Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology.Am J Clin Pathol2021
  • 1 - 50 of 269

Recommended Authors

Simpa S Salami
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 6
Steven Hazell
Royal Marsden NHS Foundation Trust
Career Start Year 2011
Number of shared co-authors 7
Brian D Robinson
Sandra and Edward Meyer Cancer Center
Career Start Year 2008
Number of shared co-authors 16
Jeffrey J Tosoian
Vanderbilt University Medical Center
Career Start Year 2008
Number of shared co-authors 8
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 24
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 16
Huihui Ye
College of Optical Science and Engineering, Zhejiang University
Career Start Year 2004
Number of shared co-authors 8
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 16
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 18
Lakshmi P Kunju
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2002
Number of shared co-authors 14
Mathieu Latour
Centre Hospitalier de l'Universite de Montreal
Career Start Year 2001
Number of shared co-authors 19
Robert Jeffrey Karnes
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 19
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 13
Vincent J Gnanapragasam
University of Cambridge
Career Start Year 1999
Number of shared co-authors 15
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 13
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 15
Niall M Corcoran
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 11
Todd M Morgan
University of Michigan ann arbor
Career Start Year 1997
Number of shared co-authors 14
David Clouston
Career Start Year 1995
Number of shared co-authors 21
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 22
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 19
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 31
Mark Frydenberg
Monash University
Career Start Year 1988
Number of shared co-authors 23
Alan W Partin
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1987
Number of shared co-authors 17
Armen Aprikian
McGill University Health Centre, McGill University
Career Start Year 1987
Number of shared co-authors 19
Freddie C Hamdy
University of Oxford
Career Start Year 1987
Number of shared co-authors 46
Dominique Trudel
Institut du cancer de Montreal
Career Start Year 1985
Number of shared co-authors 31
Eric A Klein
Cleveland Clinic
Career Start Year 1984
Number of shared co-authors 35
Bruce J Trock
Johns Hopkins University School of Medicine
Career Start Year 1984
Number of shared co-authors 15
Lawrence D True
University of Washington School of Medicine
Career Start Year 1980
Number of shared co-authors 16

Collaborators

Monique J Roobol
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 54
Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 48
Esther I Verhoef
Erasmus University Medical Center
Co-authored papers 29
Charlotte F Kweldam
Anser Prostate Operation Clinic, Maasstad Hospital
Co-authored papers 26
Guido Jenster
Erasmus University Medical Center
Co-authored papers 23
Sebastiaan Remmers
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 15
Agnes Marije Hoogland
Erasmus Medical Center
Co-authored papers 14
Inge M van Oort
Radboud University Medical Center
Co-authored papers 10
Roderick C N van den Bergh
St. Antonius Hospital
Co-authored papers 9
Lambertus A Kiemeney
Co-authored papers 8
Ewout W Steyerberg
Leiden University Medical Center
Co-authored papers 8
Ren?? B??ttcher
Universitat Pompeu Fabra
Co-authored papers 7
Alexandre R Zlotta
University Health Network, Princess Margaret Cancer Center, University of Toronto
Co-authored papers 7
Katja K H Aben
Co-authored papers 6
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 6
Andrew J Evans
Princess Margaret Cancer Center, University Health Network.
Co-authored papers 6
Harmen J G van de Werken
Department of Immunology Erasmus University Medical Center
Co-authored papers 6
Lars Egevad
Karolinska Institute
Co-authored papers 6
Daniel M Berney
Barts Cancer Institute, Queen Mary University of London
Co-authored papers 5
Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Co-authored papers 5
John R Srigley
University of Toronto
Co-authored papers 5
Ronald de Wit
Erasmus MC Cancer Institute
Co-authored papers 4
Job van Riet
Erasmus MC Cancer Institute
Co-authored papers 4
Andries M Bergman
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
Co-authored papers 4
Neil E Fleshner
University of Toronto
Co-authored papers 4
Pim van der Harst
Co-authored papers 3
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Co-authored papers 3
Martijn P Lolkema
Erasmus MC Cancer Institute
Co-authored papers 3
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Co-authored papers 3
Michiel S van der Heijden
the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
Co-authored papers 3
Release 1.2